Diverging decisions on inventive step: UPC revokes Sanofi’s Cabazitaxel second medical use patent maintained by EPO
An analysis of how the EPO Boards of Appeal and the UPC Munich Local Division assessed inventive step for Sanofi’s cabazitaxel patent and why they reached opposite outcomes in parallel proceedings























































































































































































































































































